A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

被引:269
|
作者
Soragni, Alice [1 ,2 ]
Janzen, Deanna M. [3 ]
Johnson, Lisa M. [1 ,2 ]
Lindgren, Anne G. [3 ]
Anh Thai-Quynh Nguyen [1 ,2 ]
Tiourin, Ekaterina [3 ]
Soriaga, Angela B. [1 ,2 ]
Lu, Jing [4 ]
Jiang, Lin [1 ,2 ]
Faull, Kym F. [5 ]
Pellegrini, Matteo [4 ]
Memarzadeh, Sanaz [3 ,6 ,7 ]
Eisenberg, David S. [1 ,2 ]
机构
[1] Univ Calif Los Angeles, DOE Inst, HHMI, Dept Biol Chem, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, DOE Inst, HHMI, Dept Chem & Biochem, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, Mol Cell & Dev Biol, Los Angeles, CA 90095 USA
[5] Semel Inst, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA
[6] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA
[7] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA
基金
美国国家科学基金会;
关键词
MUTANT P53; IN-VIVO; CANCER-CELLS; APOPTOSIS; PATHWAY; BREAST; TP53; GAIN; REACTIVATION; RESTORATION;
D O I
10.1016/j.ccell.2015.12.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Half of all human cancers lose p53 function by missense mutations, with an unknown fraction of these containing p53 in a self-aggregated amyloid-like state. Here we show that a cell-penetrating peptide, ReACp53, designed to inhibit p53 amyloid formation, rescues p53 function in cancer cell lines and in organoids derived from high-grade serous ovarian carcinomas (HGSOC), an aggressive cancer characterized by ubiquitous p53 mutations. Rescued p53 behaves similarly to its wild-type counterpart in regulating target genes, reducing cell proliferation and increasing cell death. Intraperitoneal administration decreases tumor proliferation and shrinks xenografts in vivo. Our data show the effectiveness of targeting a specific aggregation defect of p53 and its potential applicability to HGSOCs.
引用
收藏
页码:90 / 103
页数:14
相关论文
共 50 条
  • [41] P53 MUTATIONS IN GASTRIC CARCINOMAS
    SERUCA, R
    DAVID, L
    HOLM, R
    NESLAND, JM
    FANGAN, BM
    CASTEDO, S
    SOBRINHOSIMOES, M
    BORRESEN, AL
    BRITISH JOURNAL OF CANCER, 1992, 65 (05) : 708 - 710
  • [42] Acetylation halts missense mutant p53 aggregation and rescues tumor suppression in non-small cell cancers
    Xu, Daxin
    Qian, Wei
    Yang, Zhenkun
    Zhang, Zhenhao
    Sun, Ping
    Wan, Quan
    Yin, Ying
    Hu, Yaling
    Gong, Lingli
    Zhang, Bo
    Yang, Xusheng
    Pu, Zhening
    Lu, Peihua
    Zou, Jian
    ISCIENCE, 2023, 26 (07)
  • [43] A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
    Ladds, Marcus J. G. W.
    van Leeuwen, Ingeborg M. M.
    Drummond, Catherine J.
    Chu, Su
    Healy, Alan R.
    Popova, Gergana
    Fernandez, Andres Pastor
    Mollick, Tanzina
    Darekar, Suhas
    Sedimbi, Saikiran K.
    Nekulova, Marta
    Sachweh, Marijke C. C.
    Campbell, Johanna
    Higgins, Maureen
    Tuck, Chloe
    Popa, Mihaela
    Safont, Mireia Mayoral
    Gelebart, Pascal
    Fandalyuk, Zinayida
    Thompson, Alastair M.
    Svensson, Richard
    Gustavsson, Anna-Lena
    Johansson, Lars
    Farnegardh, Katarina
    Yngve, Ulrika
    Saleh, Aljona
    Haraldsson, Martin
    D'Hollander, Agathe C. A.
    Franco, Marcela
    Zhao, Yan
    Hakansson, Maria
    Walse, Bjorn
    Larsson, Karin
    Peat, Emma M.
    Pelechano, Vicent
    Lunec, John
    Vojtesek, Borivoj
    Carmena, Mar
    Earnshaw, William C.
    McCarthy, Anna R.
    Westwood, Nicholas J.
    Arsenian-Henriksson, Marie
    Lane, David P.
    Bhatia, Ravi
    McCormack, Emmet
    Lain, Sonia
    NATURE COMMUNICATIONS, 2018, 9
  • [44] A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
    Ladds, Marcus J. G. W.
    van Leeuwen, Ingeborg M. M.
    Drummond, Catherine J.
    Chu, Su
    Healy, Alan R.
    Popova, Gergana
    Fernandez, Andres Pastor
    Mollick, Tanzina
    Darekar, Suhas
    Sedimbi, Saikiran K.
    Nekulova, Marta
    Sachweh, Marijke C. C.
    Campbell, Johanna
    Higgins, Maureen
    Tuck, Chloe
    Popa, Mihaela
    Safont, Mireia Mayoral
    Gelebart, Pascal
    Fandalyuk, Zinayida
    Thompson, Alastair M.
    Svensson, Richard
    Gustavsson, Anna-Lena
    Johansson, Lars
    Farnegardh, Katarina
    Yngve, Ulrika
    Saleh, Aljona
    Haraldsson, Martin
    D'Hollander, Agathe C. A.
    Franco, Marcela
    Zhao, Yan
    Hakansson, Maria
    Walse, Bjorn
    Larsson, Karin
    Peat, Emma M.
    Pelechano, Vicent
    Lunec, John
    Vojtesek, Borivoj
    Carmena, Mar
    Earnshaw, William C.
    McCarthy, Anna R.
    Westwood, Nicholas J.
    Arsenian-Henriksson, Marie
    Lane, David P.
    Bhatia, Ravi
    McCormack, Emmet
    Lain, Sonia
    NATURE COMMUNICATIONS, 2018, 9
  • [45] A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
    Bernal, Federico
    Wade, Mark
    Godes, Marina
    Davis, Tina N.
    Whitehead, David G.
    Kung, Andrew L.
    Wahl, Geoffrey M.
    Walensky, Loren D.
    CANCER CELL, 2010, 18 (05) : 411 - 422
  • [46] Target p53 functionally null ovarian cancers for p53 gene replacement: Not all p53 mutations are created equal!
    Buller, RE
    Shahin, MS
    Hughes, JH
    Sorosky, JI
    Anderson, B
    Sood, AK
    CANCER GENE THERAPY, 1999, 6 (06) : S4 - S4
  • [47] Targeting p53 aggregation in ovarian cancer chemoresistant cells
    Yang-Hartwich, Yang
    Cardenas, Carlos
    Pitruzzello, Mary
    Lima, Eydis
    Alvero, Ayesha B.
    Mor, Gil
    CANCER RESEARCH, 2015, 75
  • [48] P53 MUTATIONS AND P53 PROTEIN ACCUMULATION AND COMPARTMENTALIZATION IN LARGE-BOWEL CARCINOMAS
    BOSARI, S
    VIALE, G
    RONCALLI, M
    GRAZIANI, D
    BORSANI, G
    LEE, AKC
    COGGI, G
    LABORATORY INVESTIGATION, 1995, 72 (01) : A58 - A58
  • [49] Ninjurinl, a target of p53, modulates p53-dependent tumor suppression in vivo
    Yang, Hee Jung
    Cho, Seong Jun
    Zhang, Jin
    Yan, Wensheng
    Chen, Xinbin
    CANCER RESEARCH, 2016, 76
  • [50] Alternative splicing of p53 and p73: the novel p53 splice variant p53δ is an independent prognostic marker in ovarian cancer
    Hofstetter, G.
    Berger, A.
    Fiegl, H.
    Slade, N.
    Zoric, A.
    Holzer, B.
    Schuster, E.
    Mobus, V. J.
    Reimer, D.
    Daxenbichler, G.
    Marth, C.
    Zeimet, A. G.
    Concin, N.
    Zeillinger, R.
    ONCOGENE, 2010, 29 (13) : 1997 - 2004